Dan Ziegler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1895600/publications.pdf

Version: 2024-02-01

132 papers	14,952 citations	30070 54 h-index	18647 119 g-index
146 all docs	146 docs citations	146 times ranked	11844 citing authors

#	Article	IF	Citations
1	Diagnostic Tools, Biomarkers, and Treatments in Diabetic polyneuropathy and Cardiovascular Autonomic Neuropathy. Current Diabetes Reviews, 2022, 18, .	1.3	6
2	The Role of Biofactors in Diabetic Microvascular Complications. Current Diabetes Reviews, 2022, 18, .	1.3	16
3	Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations. Diabetes Research and Clinical Practice, 2022, 186, 109063.	2.8	66
4	Differences in the prevalence of erectile dysfunction between novel subgroups of recent-onset diabetes. Diabetologia, 2022, 65, 552-562.	6.3	14
5	BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy. BMJ Open, 2022, 12, e057142.	1.9	9
6	High-intensity interval training for 12Âweeks improves cardiovascular autonomic function but not somatosensory nerve function and structure in overweight men with type 2 diabetes. Diabetologia, 2022, 65, 1048-1057.	6.3	8
7	Effect of obesity on the associations of 25-hydroxyvitamin D with prevalent and incident distal sensorimotor polyneuropathy: population-based KORA F4/FF4 study. International Journal of Obesity, 2022, 46, 1366-1374.	3.4	2
8	Peripheral Ion Channel Gene Screening in Painful- and Painless-Diabetic Neuropathy. International Journal of Molecular Sciences, 2022, 23, 7190.	4.1	9
9	Association of cardiac autonomic dysfunction with higher levels of plasma lipid metabolites in recent-onset type 2 diabetes. Diabetologia, 2021, 64, 458-468.	6.3	20
10	Interaction between magnesium and methylglyoxal in diabetic polyneuropathy and neuronal models. Molecular Metabolism, 2021, 43, 101114.	6.5	7
11	Cumulative long-term recurrence of diabetic foot ulcers in two cohorts from centres in Germany and the Czech Republic. Diabetes Research and Clinical Practice, 2021, 172, 108621.	2.8	11
12	Current concepts in the management of diabetic polyneuropathy. Journal of Diabetes Investigation, 2021, 12, 464-475.	2.4	56
13	Associations of cells from both innate and adaptive immunity with lower nerve conduction velocity: the Maastricht Study. BMJ Open Diabetes Research and Care, 2021, 9, e001698.	2.8	4
14	Association of persistent organic pollutants with sensorimotor neuropathy in participants with and without diabetes or prediabetes: Results from the population-based KORA FF4 study. International Journal of Hygiene and Environmental Health, 2021, 235, 113752.	4.3	2
15	Diabetic Neuropathy. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, S70-S81.	1.2	14
16	Progression and regression of nerve fibre pathology and dysfunction early in diabetes over 5 years. Brain, 2021, 144, 3251-3263.	7.6	14
17	Neuron-specific biomarkers predict hypo- and hyperalgesia in individuals with diabetic peripheral neuropathy. Diabetologia, 2021, 64, 2843-2855.	6.3	25
18	Double-blind, randomized, placebo-controlled crossover trial of alpha-lipoic acid for the treatment of fibromyalgia pain: the IMPALA trial. Pain, 2021, 162, 561-568.	4.2	10

#	Article	IF	Citations
19	Expansion and Impaired Mitochondrial Efficiency of Deep Subcutaneous Adipose Tissue in Recent-Onset Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1331-e1343.	3.6	13
20	Treatment with benfotiamine in patients with diabetic sensorimotor polyneuropathy: A double-blind, randomized, placebo-controlled, parallel group pilot study over 12â€¯months. Journal of Diabetes and Its Complications, 2020, 34, 107757.	2.3	5
21	NADPH Oxidase Inhibition: Preclinical and Clinical Studies in Diabetic Complications. Antioxidants and Redox Signaling, 2020, 33, 415-434.	5.4	41
22	Impairment in Baroreflex Sensitivity in Recent-Onset Type 2 Diabetes Without Progression Over 5 Years. Diabetes, 2020, 69, 1011-1019.	0.6	16
23	Polyneuropathy is inadequately treated despite increasing symptom intensity in individuals with and without diabetes (PROTECT followâ€up study). Journal of Diabetes Investigation, 2020, 11, 1272-1277.	2.4	12
24	Association of Long-Term Air Pollution with Prevalence and Incidence of Distal Sensorimotor Polyneuropathy: KORA F4/FF4 Study. Environmental Health Perspectives, 2020, 128, 127013.	6.0	13
25	Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes and Endocrinology,the, 2019, 7, 684-694.	11.4	364
26	Augmented Corneal Nerve Fiber Branching in Painful Compared With Painless Diabetic Neuropathy. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6220-6228.	3.6	12
27	A gain-of-function sodium channelÎ²2-subunit mutation in painful diabetic neuropathy. Molecular Pain, 2019, 15, 174480691984980.	2.1	38
28	Novel Insights into Sensorimotor and Cardiovascular Autonomic Neuropathy from Recent-Onset Diabetes and Population-Based Cohorts. Trends in Endocrinology and Metabolism, 2019, 30, 286-298.	7.1	35
29	General and Abdominal Obesity and Incident Distal Sensorimotor Polyneuropathy: Insights Into Inflammatory Biomarkers as Potential Mediators in the KORA F4/FF4 Cohort. Diabetes Care, 2019, 42, 240-247.	8.6	64
30	German Diabetes Study â€“ Baseline data of retinal layer thickness measured by <scp>SD</scp>â€<scp>OCT</scp> in early diabetes mellitus. Acta Ophthalmologica, 2019, 97, e303-e307.	1.1	7
31	Emerging Biomarkers, Tools, and Treatments for Diabetic Polyneuropathy. Endocrine Reviews, 2019, 40, 153-192.	20.1	140
32	Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy. BMJ Open Diabetes Research and Care, 2019, 7, e000752.	2.8	12
33	Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (PROTECT study). Diabetes Research and Clinical Practice, 2018, 139, 147-154.	2.8	45
34	Myeloperoxidase, superoxide dismutaseâ€3, cardiometabolic risk factors, and distal sensorimotor polyneuropathy: The KORA F4/FF4 study. Diabetes/Metabolism Research and Reviews, 2018, 34, e3000.	4.0	18
35	Neuropathy in Diabetes: â€œOne Cannot Begin It Too Soonâ€• Angiology, 2018, 69, 752-754.	1.8	17
36	Association of Lower Cardiovagal Tone and Baroreflex Sensitivity With Higher Liver Fat Content Early in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1130-1138.	3.6	28

#	Article	IF	Citations
37	Differential associations of lower cardiac vagal tone with insulin resistance and insulin secretion in recently diagnosed type 1 and type 2 diabetes. Metabolism: Clinical and Experimental, 2018, 79, 1-9.	3.4	25
38	Constant hepatic ATP concentrations during prolonged fasting and absence of effects of Cerbomed NemosÂ® on parasympathetic tone and hepatic energy metabolism. Molecular Metabolism, 2018, 7, 71-79.	6.5	17
39	Neuropathic pain is not adequately treated in the older general population: Results from the KORA F4 survey. Pharmacoepidemiology and Drug Safety, 2018, 27, 806-814.	1.9	16
40	A Systemic Inflammatory Signature Reflecting Cross Talk Between Innate and Adaptive Immunity Is Associated With Incident Polyneuropathy: KORA F4/FF4 Study. Diabetes, 2018, 67, 2434-2442.	0.6	36
41	Inflammatory markers are associated with cardiac autonomic dysfunction in recent-onset type 2 diabetes. Heart, 2017, 103, 63-70.	2.9	51
42	Proinflammatory Cytokines Predict the Incidence and Progression of Distal Sensorimotor Polyneuropathy: KORA F4/FF4 Study. Diabetes Care, 2017, 40, 569-576.	8.6	88
43	Predictors of response to treatment with actovegin for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy. Journal of Diabetes and Its Complications, 2017, 31, 1181-1187.	2.3	15
44	Differential Patterns of Impaired Cardiorespiratory Fitness and Cardiac Autonomic Dysfunction in Recently Diagnosed Type 1 and Type 2 Diabetes. Diabetes Care, 2017, 40, 246-252.	8.6	26
45	Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care, 2017, 40, 136-154.	8.6	1,452
46	Cardiorespiratory Fitness and Cardiac Autonomic Function in Diabetes. Current Diabetes Reports, 2017, 17, 125.	4.2	21
47	Patterns of cutaneous nerve fibre loss and regeneration in type 2 diabetes with painful and painless polyneuropathy. Diabetologia, 2017, 60, 2495-2503.	6.3	54
48	Lower serum extracellular superoxide dismutase levels are associated with polyneuropathy in recent-onset diabetes. Experimental and Molecular Medicine, 2017, 49, e394-e394.	7.7	29
49	Association of transketolase polymorphisms with measures of polyneuropathy in patients with recently diagnosed diabetes. Diabetes/Metabolism Research and Reviews, 2017, 33, e2811.	4.0	22
50	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Testing for Autonomic And Somatic Nerve Dysfunction. Endocrine Practice, 2017, 23, 1472-1478.	2.1	18
51	Early detection of neuropathy in leprosy: a comparison of five tests for field settings. Infectious Diseases of Poverty, 2017, 6, 115.	3.7	8
52	Spatial analysis improves the detection of early corneal nerve fiber loss in patients with recently diagnosed type 2 diabetes. PLoS ONE, 2017, 12, e0173832.	2.5	12
53	Innovations in the Management of Musculoskeletal Pain With Alpha-Lipoic Acid (IMPALA Trial): Study protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of Alpha-Lipoic Acid for the Treatment of Fibromyalgia Pain. JMIR Research Protocols, 2017, 6, e41.	1.0	5
54	Emerging drugs for diabetic peripheral neuropathy and neuropathic pain. Expert Opinion on Emerging Drugs, 2016, 21, 393-407.	2.4	32

#	Article	IF	Citations
55	Cohort profile: the German Diabetes Study (GDS). Cardiovascular Diabetology, 2016, 15, 59.	6.8	97
56	Adiponectin, markers of subclinical inflammation and nerve conduction in individuals with recently diagnosed type 1 and type 2 diabetes. European Journal of Endocrinology, 2016, 174, 433-443.	3.7	38
57	Predictors of improvement and progression of diabetic polyneuropathy following treatment with Î±-lipoic acid for 4years in the NATHAN 1 trial. Journal of Diabetes and Its Complications, 2016, 30, 350-356.	2.3	66
58	Corneal confocal microscopy: Recent progress in the evaluation of diabetic neuropathy. Journal of Diabetes Investigation, 2015, 6, 381-389.	2.4	51
59	A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain. Pain, 2015, 156, 2013-2020.	4.2	74
60	Treatment withÎ±-Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic Polyneuropathy Who Responded to Initial 4-Week High-Dose Loading. Journal of Diabetes Research, 2015, 2015, 1-8.	2.3	27
61	Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015. Review of Diabetic Studies, 2015, 12, 48-62.	1.3	150
62	Overexpression of cutaneous mitochondrial superoxide dismutase in recent-onset type 2 diabetes. Diabetologia, 2015, 58, 1621-1625.	6.3	9
63	Response to research letter in relation to paper by Bongaerts et al., A Clinical Screening Score for Diabetic Polyneuropathy: KORA F4 and AusDiab Studies (A single question screening test for the) Tj ETQq1 1 0.784314 rgBT /Overloc	2.3	
64	Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: the KORA S4 survey. Diabetologia, 2015, 58, 1118-1128.	6.3	85
65	Effect of Low-Energy Diets Differing in Fiber, Red Meat, and Coffee Intake on Cardiac Autonomic Function in Obese Individuals With Type 2 Diabetes. Diabetes Care, 2015, 38, 1750-1757.	8.6	27
66	Normative Values for Corneal Nerve Morphology Assessed Using Corneal Confocal Microscopy: A Multinational Normative Data Set. Diabetes Care, 2015, 38, 838-843.	8.6	150
67	High prevalence of diagnosed and undiagnosed polyneuropathy in subjects with and without diabetes participating in a nationwide educational initiative (PROTECT study). Journal of Diabetes and Its Complications, 2015, 29, 998-1002.	2.3	36
68	Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes. BMJ Open, 2015, 5, e006559.	1.9	47
69	Differential Association Between Biomarkers of Subclinical Inflammation and Painful Polyneuropathy: Results From the KORA F4 Study. Diabetes Care, 2015, 38, 91-96.	8.6	36
70	From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. Journal of Diabetes and Its Complications, 2015, 29, 146-156.	2.3	75
71	Oxidative stress predicts progression of peripheral and cardiac autonomic nerve dysfunction over 6Âyears in diabetic patients. Acta Diabetologica, 2015, 52, 65-72.	2.5	36
72	Differential Patterns and Determinants of Cardiac Autonomic Nerve Dysfunction during Endotoxemia and Oral Fat Load in Humans. PLoS ONE, 2015, 10, e0124242.	2.5	10

#	Article	IF	Citations
73	Patient Expectations in the Treatment of Painful Diabetic Polyneuropathy: Results from a Non-Interventional Study. Pain Medicine, 2014, 15, 671-681.	1.9	5
74	Efficacy of Î±-lipoic acid in diabetic neuropathy. Expert Opinion on Pharmacotherapy, 2014, 15, 2721-2731.	1.8	139
75	Effectiveness of Duloxetine Compared With Pregabalin and Gabapentin in Diabetic Peripheral Neuropathic Pain. Clinical Journal of Pain, 2014, 30, 875-885.	1.9	27
76	Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms. Clinical Pharmacology: Advances and Applications, 2014, 6, 195.	1.2	18
77	Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice. Journal of Diabetes and Its Complications, 2014, 28, 698-704.	2.3	15
78	Early Detection of Nerve Fiber Loss by Corneal Confocal Microscopy and Skin Biopsy in Recently Diagnosed Type 2 Diabetes. Diabetes, 2014, 63, 2454-2463.	0.6	270
79	Epidemiology of polyneuropathy in diabetes and prediabetes. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 126, 3-22.	1.8	166
80	The Role of Sodium Channels in Painful Diabetic and Idiopathic Neuropathy. Current Diabetes Reports, 2014, 14, 538.	4.2	33
81	New vistas in the diagnosis of diabetic polyneuropathy. Endocrine, 2014, 47, 690-698.	2.3	35
82	Pronounced Reduction of Cutaneous Langerhans Cell Density in Recently Diagnosed Type 2 Diabetes. Diabetes, 2014, 63, 1148-1153.	0.6	17
83	Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. Pain, 2013, 154, 1807-1819.	4.2	428
84	Novel pathogenic pathways in diabetic neuropathy. Trends in Neurosciences, 2013, 36, 439-449.	8.6	128
85	Whither pathogenetic treatments for diabetic polyneuropathy?. Diabetes/Metabolism Research and Reviews, 2013, 29, 327-333.	4.0	68
86	Association of Subclinical Inflammation With Polyneuropathy in the Older Population. Diabetes Care, 2013, 36, 3663-3670.	8.6	76
87	Older Subjects With Diabetes and Prediabetes Are Frequently Unaware of Having Distal Sensorimotor Polyneuropathy. Diabetes Care, 2013, 36, 1141-1146.	8.6	89
88	Comment on: Fraser et al. The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes: A 24-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Diabetes Care 2012;35:1095-1097. Diabetes Care, 2012, 35, e79-e79.	8.6	4
89	Postchallenge Hyperglycemia Is Positively Associated With Diabetic Polyneuropathy. Diabetes Care, 2012, 35, 1891-1893.	8.6	55
90	Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nature Medicine, 2012, 18, 926-933.	30.7	414

#	Article	IF	Citations
91	Prediabetic Neuropathy: Does It Exist?. Current Diabetes Reports, 2012, 12, 376-383.	4.2	54
92	Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain, 2012, 153, 1148-1158.	4.2	227
93	Neuropathy in prediabetes: does the clock start ticking early?. Nature Reviews Endocrinology, 2011, 7, 682-690.	9.6	171
94	New diagnostic tests for diabetic distal symmetric polyneuropathy. Journal of Diabetes and Its Complications, 2011, 25, 44-51.	2.3	64
95	Efficacy and Safety of Antioxidant Treatment With Î±-Lipoic Acid Over 4 Years in Diabetic Polyneuropathy. Diabetes Care, 2011, 34, 2054-2060.	8.6	318
96	Neuroprotective and Anti-Oxidative Effects of the Hemodialysate Actovegin on Primary Rat Neurons in Vitro. NeuroMolecular Medicine, 2011, 13, 266-274.	3.4	50
97	Methods of investigation for cardiac autonomic dysfunction in human research studies. Diabetes/Metabolism Research and Reviews, 2011, 27, 654-664.	4.0	139
98	Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes/Metabolism Research and Reviews, 2011, 27, 639-653.	4.0	675
99	Current Concepts in the Management of Diabetic Polyneuropathy. Current Diabetes Reviews, 2011, 7, 208-220.	1.3	44
100	Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. Journal of the Peripheral Nervous System, 2010, 15, 202-207.	3.1	462
101	Residual microvascular risk in diabetes: unmet needs and future directions. Nature Reviews Endocrinology, 2010, 6, 19-25.	9.6	92
102	Neuropathy: The Crystal Ball for Cardiovascular Disease?. Diabetes Care, 2010, 33, 1688-1690.	8.6	78
103	Efficacy and Safety of Lacosamide in Painful Diabetic Neuropathy. Diabetes Care, 2010, 33, 839-841.	8.6	83
104	Painful Diabetic Neuropathy. Diabetes Care, 2009, 32, S414-S419.	8.6	75
105	Subclinical Inflammation and Diabetic Polyneuropathy. Diabetes Care, 2009, 32, 680-682.	8.6	92
106	Neuropathic Pain in Diabetes, Prediabetes and Normal Glucose Tolerance: The MONICA/KORA Augsburg Surveys S2 and S3. Pain Medicine, 2009, 10, 393-400.	1.9	201
107	Comment on Haussleiter et al.: NeuroQuick â€“ A novel bedside test for small fiber neuropathy?. European Journal of Pain, 2009, 13, 217-217.	2.8	2
108	Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with preâ€diabetes and diabetes. The KORA Myocardial Infarction Registry. European Journal of Pain, 2009, 13, 582-587.	2.8	74

#	Article	IF	Citations
109	Treatment of Symptomatic Polyneuropathy With Actovegin in Type 2 Diabetic Patients. Diabetes Care, 2009, 32, 1479-1484.	8.6	73
110	Painful diabetic neuropathy: treatment and future aspects. Diabetes/Metabolism Research and Reviews, 2008, 24, S52-S57.	4.0	126
111	Prevalence of Polyneuropathy in Pre-Diabetes and Diabetes Is Associated With Abdominal Obesity and Macroangiopathy. Diabetes Care, 2008, 31, 464-469.	8.6	346
112	Statement of Retraction. Diabetes Care, 2008, 31, S255-S255.	8.6	82
113	Prediction of Mortality Using Measures of Cardiac Autonomic Dysfunction in the Diabetic and Nondiabetic Population. Diabetes Care, 2008, 31, 556-561.	8.6	194
114	Diabetic Cardiovascular Autonomic Neuropathy. Circulation, 2007, 115, 387-397.	1.6	1,062
115	Challenges in Design of Multicenter Trials: End points assessed longitudinally for change and monotonicity. Diabetes Care, 2007, 30, 2619-2625.	8.6	109
116	Impact of Disease Characteristics on the Efficacy of Duloxetine in Diabetic Peripheral Neuropathic Pain. Diabetes Care, 2007, 30, 664-669.	8.6	72
117	Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain: Evidence-Based Findings from Post Hoc Analysis of Three Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Studies. Clinical Therapeutics, 2007, 29, 2536-2546.	2.5	115
118	Management of painful diabetic neuropathy: What is new or in the pipeline for 2007?. Current Diabetes Reports, 2007, 7, 409-415.	4.2	5
119	Diabetic Peripheral Neuropathy and Sexual Dysfunction. , 2007, , 277-312.		0
120	Oral Treatment With Î±-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy. Diabetes Care, 2006, 29, 2365-2370.	8.6	491
121	Treatment of Diabetic Polyneuropathy: Update 2006. Annals of the New York Academy of Sciences, 2006, 1084, 250-266.	3.8	53
122	New perspectives on the management of diabetic peripheral neuropathic pain. Diabetes and Vascular Disease Research, 2006, 3, 108-119.	2.0	164
123	Validation of a Novel Screening Device (NeuroQuick) for Quantitative Assessment of Small Nerve Fiber Dysfunction as an Early Feature of Diabetic Polyneuropathy. Diabetes Care, 2005, 28, 1169-1174.	8.6	52
124	Diabetic Neuropathies. Diabetes Care, 2005, 28, 956-962.	8.6	1,599
125	Oxidative Stress and Antioxidant Defense in Relation to the Severity of Diabetic Polyneuropathy and Cardiovascular Autonomic Neuropathy. Diabetes Care, 2004, 27, 2178-2183.	8.6	146
126	Thioctic Acid for Patients with Symptomatic Diabetic Polyneuropathy. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2004, 3, 173-189.	1.8	115

#	Article	IF	Citations
127	The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With Î±-Lipoic Acid. Diabetes Care, 2003, 26, 770-776.	8.6	328
128	Clinical trials for drugs against diabetic neuropathy: Can we combine scientific needs with clinical practicalities?. International Review of Neurobiology, 2002, 50, 431-463.	2.0	22
129	Time- and frequency-domain estimation of early diabetic cardiovascular autonomic neuropathy. Clinical Autonomic Research, 2001, 11, 369-376.	2.5	86
130	Diabetic cardiovascular autonomic neuropathy: Prognosis, diagnosis and treatment. Diabetes/metabolism Reviews, 1994, 10, 339-383.	0.3	234
131	Prevalence of Cardiovascular Autonomic Dysfunction Assessed by Spectral Analysis and Standard Tests of Heart-Rate Variation in Newly Diagnosed IDDM Patients. Diabetes Care, 1992, 15, 908-911.	8.6	75
132	Assessment of Cardiovascular Autonomic Function: Ageâ€related Normal Ranges and Reproducibility of Spectral Analysis, Vector Analysis, and Standard Tests of Heart Rate Variation and Blood Pressure Responses. Diabetic Medicine, 1992, 9, 166-175.	2.3	365